Circulation:B型主动脉夹层治疗:如何选择?

2015-09-30 张旭栋 MedSci原创

休斯敦德克萨斯大学医学院Afifi RO等人研究了B型主动脉夹层患者的远期结局,成果发表在8月份Circulation期刊上。背景:主动脉夹层(Aortic Dissection,AD)是最主要的主动脉上的灾难性疾病。在血管腔内时代,急性B型主动脉夹层(acute type B aortic dissection, ATBAD)的治疗最引入注目。本项研究旨在评估我们中心治疗时间已经超过13年ATB

休斯敦德克萨斯大学医学院Afifi RO等人研究了B型主动脉夹层患者的远期结局,成果发表在8月份Circulation期刊上。

背景:主动脉夹层(Aortic Dissection,AD)是最主要的主动脉上的灾难性疾病。在血管腔内时代,急性B型主动脉夹层(acute type B aortic dissection, ATBAD)的治疗最引入注目。本项研究旨在评估我们中心治疗时间已经超过13年ATBAD患者的远期结局。

方法和结果:我们回顾2001年和2014年之间ATBAD患者,分析了患者的状态(患并发症[C]与不患并发症[U])和治疗方式。我们定义cATBAD为血管破裂,入院期间影像学显示血管直径扩张,持续性疼痛,或初次入院期间脑、脊髓、内脏、肾、或周围血管灌注不足。术后的结果定义为介入前不存在灌注不足。通过使用Kaplan-Meier法和描述性统计数据对组内的结局进行比较。我们治疗了442例ATBAD患者。442例患者中,60.6%患有uATBAD,39.4%患有cATBAD。cATBAD患者中39.0%的患者进行医学处理,30.0%患者进行开放性修复,21.3%进行胸主动脉腔内修复,9.7%患者进行其他开放治疗。1年和5年的干预生存率,uATBAD 患者分别为84.8%和62.7%,行医学处理的cATBAD患者分别为61.8%和44.0%,行开放性修复的cATBAD患者分别为69.2%和开47.2%,行胸主动脉腔内修cATBAD患者分别为68.0%和42.5%,各组内比较分别为P = 0.001。结局显示,cATBAD患者各组治疗结局中有显著性差异。

结局:根据我们的经验,ATBAD患者早期和晚期结局都依赖于是否具有并发症,cATBAD患者所面临的结局情况更糟。X线监视下行开放性治疗或血管内介入治疗发现,尽管uATBAD具有良好的早期生存率,但晚期并发症仍然时有发生。目前仍然需要uATBAD患者最佳治疗的前瞻性研究。

原始出处:

Afifi RO, Sandhu HK, Leake SS, Boutrous ML, Kumar V, 3rd, Azizzadeh A, Charlton-Ouw KM, Saqib NU, Nguyen TC, Miller CC, 3rd, Safi HJ, Estrera AL (2015) Outcomes of Patients With Acute Type B (DeBakey III) Aortic Dissection: A 13-Year, Single-Center Experience. Circulation 132 (8):748-754. doi:10.1161/circulationaha.115.015302

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2058302, encodeId=dd8720583022c, content=<a href='/topic/show?id=65a4381562' target=_blank style='color:#2F92EE;'>#B型主动脉夹层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3815, encryptionId=65a4381562, topicName=B型主动脉夹层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Apr 15 03:26:00 CST 2016, time=2016-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415011, encodeId=50a01415011c2, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Fri Oct 02 01:26:00 CST 2015, time=2015-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519507, encodeId=6ac7151950e26, content=<a href='/topic/show?id=b63a3323558' target=_blank style='color:#2F92EE;'>#动脉夹层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33235, encryptionId=b63a3323558, topicName=动脉夹层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5711287462, createdName=mhzhuang@stu.e, createdTime=Fri Oct 02 01:26:00 CST 2015, time=2015-10-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2058302, encodeId=dd8720583022c, content=<a href='/topic/show?id=65a4381562' target=_blank style='color:#2F92EE;'>#B型主动脉夹层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3815, encryptionId=65a4381562, topicName=B型主动脉夹层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Apr 15 03:26:00 CST 2016, time=2016-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415011, encodeId=50a01415011c2, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Fri Oct 02 01:26:00 CST 2015, time=2015-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519507, encodeId=6ac7151950e26, content=<a href='/topic/show?id=b63a3323558' target=_blank style='color:#2F92EE;'>#动脉夹层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33235, encryptionId=b63a3323558, topicName=动脉夹层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5711287462, createdName=mhzhuang@stu.e, createdTime=Fri Oct 02 01:26:00 CST 2015, time=2015-10-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2058302, encodeId=dd8720583022c, content=<a href='/topic/show?id=65a4381562' target=_blank style='color:#2F92EE;'>#B型主动脉夹层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3815, encryptionId=65a4381562, topicName=B型主动脉夹层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Apr 15 03:26:00 CST 2016, time=2016-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415011, encodeId=50a01415011c2, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Fri Oct 02 01:26:00 CST 2015, time=2015-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519507, encodeId=6ac7151950e26, content=<a href='/topic/show?id=b63a3323558' target=_blank style='color:#2F92EE;'>#动脉夹层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33235, encryptionId=b63a3323558, topicName=动脉夹层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5711287462, createdName=mhzhuang@stu.e, createdTime=Fri Oct 02 01:26:00 CST 2015, time=2015-10-02, status=1, ipAttribution=)]

相关资讯

Heart:D-二聚体和CRP可预测主动脉夹层院内死亡

  首都医科大学附属北京安贞医院的马长生和董建增等探讨了血浆D—二聚体和C反应蛋白(CRP)在预测急性主动脉夹层(AD)院内死亡所起的作用,结果发现,血浆D—二聚体≥5.67 μg/mL、CRP ≥11.21 mg/L和A型急性主动脉夹层是AD院内死亡的重要危险因素,且与其独立相关。论文6月28日在线发表于《心脏》(Heart)杂志。  该单中心前瞻性研究入选了114例急性AD患者,测定

NEJM:氯沙坦与阿替洛尔治疗马凡综合征的效果一致

主动脉根部夹层是马凡综合征的首要致死原因。目前β受体阻滞剂是临床的标准治疗,但研究表明,氯沙坦减缓主动脉夹层扩张的效果优于β受体阻滞剂。为了比较氯沙坦和阿替洛尔治疗主动脉根部扩张的效果,美国Ronald V. Lacro等人用随机对照试验将患马凡综合征的儿童和青年分成氯沙坦治疗组和阿替洛尔治疗组,该项研究发表于今年11月的新英格兰医学杂志上。研究纳入了2007年1月至2011年2月,共21个临床中

主动脉夹层,选介入还是外科?

             主动脉夹层(AD)诊断分型以及若首次行外科手术而非介入治疗,就可避免主动脉夹层再发。上海交通大学医学院附属瑞金医院臧旺福教授对此发表了见解。       主动脉夹层(AD)是心血管病的高危病种,